Login to Your Account

One patent down in race to oral MS generic competition

By Mari Serebrov
Regulatory Editor

Thursday, April 13, 2017

Being the first to market and having commercial success do not prove novelty, the U.S. Court of Appeals for the Federal Circuit ruled Wednesday in affirming that the PTAB rightly invalidated one of four patents protecting Novartis AG's Gilenya from generic competition.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription